Deciphera revives hopes for Qinlock with subgroup analysis, plots new PhIII — but market reaction is muted
More than a year ago, disappointing data from a key Phase III seemingly shattered Deciphera’s hopes of moving its kinase inhibitor into earlier lines of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
